$19 Mln
$-4 Mln
--
As on 22-Sep-2023 16:00 EDT
$-0.01
•
-0.70%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Nephros (NEPH)
| 21.55 | -14.03 | -18.50 | 38.24 | -39.38 | -23.03 | -18.42 |
|
S&P BSE Sensex*
| 8.52 | 1.18 | 4.83 | 13.64 | 21.78 | 12.71 | 12.73 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
|---|---|---|---|---|---|---|---|
|
Nephros (NEPH)
| -80.34 | -31.24 | -13.77 | 93.96 | 26.48 | 22.94 | 69.93 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Nephros Inc. (NEPH) stood at $ 12 Mln as on 31-Mar-23
The share price of Nephros Inc. (NEPH) is $1.410000 (NASDAQ) as of 22-Sep-2023 16:00 EDT. Nephros Inc. (NEPH) has given a return of -39.38% in the last 3 years.
Nephros Inc. (NEPH) has a market capitalisation of $ 19 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of Nephros Inc. (NEPH) is 1.65 times as on 02-Jun-2023, a -0.59% premium to its peers’ median range of 4.02 times.
Since, TTM earnings of Nephros Inc. (NEPH) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Nephros Inc. (NEPH) and enter the required number of quantities and click on buy to purchase the shares of Nephros Inc. (NEPH).
Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
The CEO & director of Mr. Andrew Astor. is Nephros Inc. (NEPH), and CFO & Sr. VP is Ms. Joleen C. Turner.
The promoters of Nephros Inc. (NEPH) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
3
|
|
|
3
|
|
|
1
|
|
|
1
|
| Nephros Inc. (NEPH) | Ratios |
|---|---|
|
Return on equity(%)
|
-73.53
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Nephros Inc. (NEPH) was $-4 Mln.
$18.77 Mln
$11.55 Mln
$-4.43 Mln
$3.84 Mln
$0.93 Mln
Moderate
$0.91 - 2.50
10,484,900
NASDAQ: NEPH
South Orange, NJ
https://www.nephros.com
Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration... products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
